Dronedarone: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[pharmacology]] and [[cardiology]], '''dronedarone''' is | In [[pharmacology]] and [[cardiology]], '''dronedarone''' is an [[anti-arrhythmia agent]] used to treat paroxysmal or persistent [[atrial fibrillation]] or [[atrial flutter]]. | ||
==Effectiveness== | ==Effectiveness== | ||
Dronedarone may reduce the rate cardiovascular events of among patients with an [[ventricular ejection fraction]] of 40% of less and [[New York Heart Association Functional Classification]] class I-III [[heart failure]] according to the ATHENA [[randomized controlled trial]].<ref name="pmid19213680">{{cite journal| author=Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C et al.| title=Effect of dronedarone on cardiovascular events in atrial fibrillation. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 7 | pages= 668-78 | pmid=19213680 | doi=10.1056/NEJMoa0803778 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19213680 }} </ref> | |||
==Pharmacology== | ==Pharmacology== | ||
| Line 11: | Line 11: | ||
===Excretion=== | ===Excretion=== | ||
===Toxicity=== | ===Toxicity=== | ||
[[Drug toxicity]] includes increased mortality among patients whose ejection fraction is less than 35% according to the ANDROMEDA [[randomized controlled trial]].<ref name="pmid18565860">{{cite journal| author=Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H et al.| title=Increased mortality after dronedarone therapy for severe heart failure. | journal=N Engl J Med | year= 2008 | volume= 358 | issue= 25 | pages= 2678-87 | pmid=18565860 | doi=10.1056/NEJMoa0800456 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18565860 }} </ref> | [[Drug toxicity]] includes increased mortality among patients whose [[ventricular ejection fraction]] is less than 35% according to the ANDROMEDA [[randomized controlled trial]].<ref name="pmid18565860">{{cite journal| author=Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H et al.| title=Increased mortality after dronedarone therapy for severe heart failure. | journal=N Engl J Med | year= 2008 | volume= 358 | issue= 25 | pages= 2678-87 | pmid=18565860 | doi=10.1056/NEJMoa0800456 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18565860 }} </ref> These patients were enrolled in the ANDROMEDA study because they had been "hospitalized with new or worsening heart failure and who had had at least one episode of shortness of breath on minimal exertion or at rest ([[New York Heart Association Functional Classification|New York Heart Association]] [NYHA] functional class III or IV) or paroxysmal nocturnal dyspnea within the month" | ||
==External links== | ==External links== | ||
{{CZMed}} | {{CZMed}} | ||
==References== <references/> | ==References== | ||
<references/> | |||
Latest revision as of 21:25, 7 July 2011
In pharmacology and cardiology, dronedarone is an anti-arrhythmia agent used to treat paroxysmal or persistent atrial fibrillation or atrial flutter.
Effectiveness
Dronedarone may reduce the rate cardiovascular events of among patients with an ventricular ejection fraction of 40% of less and New York Heart Association Functional Classification class I-III heart failure according to the ATHENA randomized controlled trial.[1]
Pharmacology
Administration
Distribution
Metabolism
Excretion
Toxicity
Drug toxicity includes increased mortality among patients whose ventricular ejection fraction is less than 35% according to the ANDROMEDA randomized controlled trial.[2] These patients were enrolled in the ANDROMEDA study because they had been "hospitalized with new or worsening heart failure and who had had at least one episode of shortness of breath on minimal exertion or at rest (New York Heart Association [NYHA] functional class III or IV) or paroxysmal nocturnal dyspnea within the month"
External links
The most up-to-date information about Dronedarone and other drugs can be found at the following sites.
- Dronedarone - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Dronedarone - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Dronedarone - Detailed information from DrugBank.
References
- ↑ Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C et al. (2009). "Effect of dronedarone on cardiovascular events in atrial fibrillation.". N Engl J Med 360 (7): 668-78. DOI:10.1056/NEJMoa0803778. PMID 19213680. Research Blogging.
- ↑ Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H et al. (2008). "Increased mortality after dronedarone therapy for severe heart failure.". N Engl J Med 358 (25): 2678-87. DOI:10.1056/NEJMoa0800456. PMID 18565860. Research Blogging.